27 October 2023 in American Journal of Transplantation
The XVI-th Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from 19th-23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30th anniversary of the first Banff Classification, pre-meeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis. In a post-meeting survey, agreement was reached on the delineation of the following phenotypes: (1) "Probable antibody-mediated rejection (AMR)", which represents DSA-positive cases with some histological features of AMR but below current thresholds for a definitive AMR diagnosis; and (2) "Microvascular inflammation (MVI), DSA-negative and C4d-negative", a phenotype of unclear cause requiring further study, which represents cases with MVI not explained by DSA. Although biopsy-based transcript diagnostics are considered promising and remain an integral part of the Banff Classification (limited to diagnosis of AMR), further work needs to be done to agree on the exact classifiers, thresholds, and clinical context of use.
20 July 2017 in Journal of the American Society of Nephrology
Despite more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor-specific antibody (dnDSA) development correlates with tacrolimus trough levels and the recipient’s individualized alloimmune risk determined by HLA-DR/DQ epitope mismatch. A cohort of 596 renal transplant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined using HLAMatchmaker software. We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and the mean tacrolimus levels before dnDSA development in the context of HLA-DR/DQ eplet mismatch. HLA-DR/DQ eplet mismatch was a significant multivariate predictor of dnDSA development. Recipients treated with a cyclosporin regimen had a 2.7-fold higher incidence of dnDSA development than recipients on a tacrolimus regimen. Recipients treated with tacrolimus who developed HLA-DR/DQ dnDSA had a higher proportion of tacrolimus trough levels 6 months before dnDSA development in the same patients. Recipients with a high-risk HLA eplet mismatch score were less likely to tolerate low tacrolimus levels without developing dnDSA. We conclude that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dnDSA development. Recipients with high HLA alloimmune risk should not target tacrolimus levels <5 ng/ml unless essential, and monitoring for dnDSA may be advisable in this setting.
10 November 2018 in American Journal of Transplantation
Alloimmune risk stratification in renal transplantation has lacked the necessary prognostic biomarkers to personalize recipient care or optimize clinical trials. HLA molecular mismatch improves precision compared to traditional antigen mismatch but has not been studied in detail at the individual molecule level. This study evaluated 664 renal transplant recipients and correlated HLA‐DR/DQ single molecule eplet mismatch with serologic, histologic, and clinical outcomes. Compared to traditional HLA‐DR/DQ whole antigen mismatch HLA‐DR/DQ single molecule eplet mismatch improved the correlation with de novo donor‐specific antibody (dnDSA) development (AUC 0.54 versus 0.84) and allowed recipients to be stratified into low, intermediate, and high alloimmune risk categories. These risk categories were significantly correlated with primary alloimmune events including Banff ≥1A T‐cell mediated rejection (p=0.0006), HLA‐DR/DQ dnDSA development (p<0.0001), antibody‐mediated rejection (p<0.0001), as well as all cause graft loss (p=0.0012) and each of these correlations persisted in multivariate models. Thus, HLA‐DR/DQ single molecule eplet mismatch may represent a precise, reproducible, and widely available prognostic biomarker that can be applied to tailor immunosuppression or design clinical trials based on individual patient risk.
27 April 2020 in American Journal of Transplantation
The purpose of the STAR 2019 Working Group was to build on findings from the initial STAR report to further clarify the expectations, limitations, perceptions, and utility of alloimmune assays that are currently in use or in development for risk assessment in the setting of organ transplantation. The goal was to determine the precision and clinical feasibility/utility of such assays in evaluating both memory and primary alloimmune risks. The process included a critical review of biologically driven, state of the art, clinical diagnostics literature by experts in the field, and an open public forum in a face‐to‐face meeting to promote broader engagement of the AST and ASHI membership. This report summarizes the literature review and the workshop discussions. Specifically, it highlights: (i) available assays to evaluate the attributes of HLA antibodies, and their utility both as clinical diagnostics and as research tools to evaluate the effector mechanisms driving rejection; (ii) potential assays to assess the presence of alloimmune T‐ and B‐cell memory; and (iii) progress in the development of HLA molecular mismatch computational scores as a potential prognostic biomarker for primary alloimmunity and its application in research trial design.
1 August 2018 in Transplantation
Antibody-mediated rejection is a major cause of premature graft loss in kidney transplantation. Multiple scoring systems are available to assess the HLA mismatch between donors and recipients at the molecular level, however, their correlation with the development of de novo donor-specific antibody (dnDSA) has not been compared in recipients on active immunosuppression. HLA-DRβ1/3/4/5/DQα1β1 molecular mismatch was determined using eplet analysis, amino acid mismatch, and electrostatic mismatch for 596 renal transplant recipients and correlated with HLA-DR/DQ dnDSA development. The molecular mismatch scores were evaluated in multivariate models of posttransplant dnDSA free survival. Eplet mismatch correlated with amino acid mismatch and electrostatic mismatch (R2=0.85-0.96). HLA-DR dnDSA free survival correlated with HLA-DR eplet mismatch (HR 2.50 per 10 eplets mismatched, p<0.0001), amino acid mismatch (HR 1.49 per 10 amino acids mismatched, p<0.0001), and electrostatic mismatch (HR 1.23 per 10 units mismatched, p<0.0001). HLA-DQ dnDSA free survival correlated with HLA-DQ eplet mismatch (HR 1.98 per 10 eplets mismatched, p<0.0001), amino acid mismatch (HR 1.24 per 10 amino acids mismatched, p<0.0001), and electrostatic mismatch (HR 1.14 per 10 units mismatched, p<0.0001). All 3 methods were significant multivariate correlates of dnDSA development after adjustment for recipient age, baseline immunosuppression, and nonadherence. HLA molecular mismatch represents a precise method of alloimmune risk assessment for renal transplant patients. This report highlights that the use of one method over the other is likely to be driven by familiarity and ease of use as highly correlated results are produced by each method.
30 October 2021 in American Journal of Transplantation
The prevalence and long-term impact of T-cell mediated rejection (TCMR) is poorly defined in the modern era of tacrolimus/mycophenolate-based maintenance therapy. This observational study evaluated 775 kidney transplant recipients with serial histology and correlated TCMR events with the risk of graft loss. After a ~30% incidence of a first Banff Borderline or greater TCMR detected on for-cause (17%) or surveillance (13%) biopsies, persistent (37.4%) or subsequent (26.3%) TCMR occurred in 64% of recipients on follow-up biopsies. Alloimmune risk categories based on HLA-DR/DQ single molecule eplet molecular mismatch correlated with the number of TCMR events (p=0.002) and Banff TCMR grade (p=0.007). Both a first and second TCMR event correlated with death-censored and all-cause graft loss when adjusted for baseline covariates and other significant time-dependent covariates such as DGF and ABMR. Therefore, a substantial portion of kidney transplant recipients, especially those with intermediate and high HLA-DR/DQ molecular mismatch scores, remain under-immunosuppressed, which in turn identifies the need for novel agents that can more effectively prevent or treat TCMR.